Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noveris Health SciencesMYCOF 23 Debt-to-EBITDA is -0.07 as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100. Among 680 Drug Manufacturers companies, Noveris Health Sciences ranks better than 79.71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Noveris Health Sciences's Debt-to-EBITDA or its related term are showing as below:
MYCOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.98 Med: -0.13 Max: 3.05
Current: 0.23
During the past 13 years, the highest Debt-to-EBITDA Ratio of Noveris Health Sciences was 3.05. The lowest was -3.98. And the median was -0.13.
MYCOF's Debt-to-EBITDA is ranked better than 79.71% of 680
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs MYCOF: 0.23
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Noveris Health Sciences Debt-to-EBITDA Related Terms
Noveris Health Sciences Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Noveris Health Sciences (MYCOF) has a Debt-to-EBITDA of -0.07 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Noveris Health Sciences. According to the industry distribution chart, Noveris Health Sciences ranks #138 out of 680 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Noveris Health Sciences' Debt-to-EBITDA too high?
Noveris Health Sciences' current Debt-to-EBITDA is -0.07. Based on the distribution chart, Noveris Health Sciences ranks #138 out of 680 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #138 out of 680 companies for Debt-to-EBITDA. This places Noveris Health Sciences in the top 20% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Noveris Health Sciences. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Debt-to-EBITDA is -0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Noveris Health Sciences (MYCOF) has a current Debt-to-EBITDA of -0.07. The current Debt-to-EBITDA is -0.07. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Debt-to-EBITDA is -0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
